James Emmett Herndon II

Current research interests have application to the design and analysis of cancer clinical trials. Specifically, interests include the use of time-dependent covariables within survival models, the design of phase II cancer clinical trials which minimize some of the logistical problems associated with their conduct, and the analysis of longitudinal studies with informative censoring (in particular, quality of life studies of patients with advanced cancer).

Current Appointments & Affiliations

Professor of Biostatistics & Bioinformatics · 2022 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics

Member of the Duke Cancer Institute · 1988 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications

Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.

Journal Article J Neurooncol · November 5, 2025 PURPOSE: With a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress are essential in patient clinical care. Mindfulness meditation is a mind-body therapy that is being investigated as a non-pharmacological strate ... Full text Link to item Cite

A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.

Journal Article Cancer · November 1, 2025 BACKGROUND: Treatment options for patients with advanced non-small cell lung cancer (NSCLC) with disease progression following immune checkpoint inhibitor (ICI) and platinum-based chemotherapy are limited. GT103 is a fully human immunoglobulin G3 monoclona ... Full text Link to item Cite

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma.

Journal Article Sci Rep · October 23, 2025 Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically approved PCSK9 in ... Full text Link to item Cite

View All Publications

Education, Training & Certifications

University of North Carolina, Chapel Hill · 1988 Ph.D.

James Emmett Herndon II

Overview

Current Appointments & Affiliations

Recent Publications

Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.

A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma.

Recent Grants

Inflammasomes - a driver of sexual dimorphism to glioma therapies

McCain/Bayh Glioblastoma Consortium

Comparison of convection enhanced delivery systems in a clinical study of recurrent Grade 3-4 glioma patients

Education, Training & Certifications